117 related articles for article (PubMed ID: 22377846)
1. Tailoring neoadjuvant chemotherapy for locally advanced breast cancer: a historical prospective study.
Zer A; Rizel S; Braunstein R; Yerushalmi R; Hendler D; Neimann V; Cioreuru N; Sulkes A; Stemmer SM
Chemotherapy; 2012; 58(2):95-101. PubMed ID: 22377846
[TBL] [Abstract][Full Text] [Related]
2. Concurrent bevacizumab with a sequential regimen of doxorubicin and cyclophosphamide followed by docetaxel and capecitabine as neoadjuvant therapy for HER2- locally advanced breast cancer: a phase II trial of the NSABP Foundation Research Group.
Rastogi P; Buyse ME; Swain SM; Jacobs SA; Robidoux A; Liepman MK; Pajon ER; Dy PA; Posada JG; Melnik MK; Piette F; Geyer CE; Mamounas EP; Wolmark N
Clin Breast Cancer; 2011 Aug; 11(4):228-34. PubMed ID: 21684812
[TBL] [Abstract][Full Text] [Related]
3. Neoadjuvant chemotherapy of breast cancer.
Garces CA; Cance WG
Am Surg; 2004 Jul; 70(7):565-9. PubMed ID: 15279176
[TBL] [Abstract][Full Text] [Related]
4. High pathologic complete response in HER 2-positive locally advanced breast cancer after primary systemic chemotherapy with weekly docetaxel and epirubicin.
Chen SC; Chang HK; Lin YC; Hsueh S; Cheung YC; Leung WM; Tsai CS; Lo YF; Tsai HP; Shen SC; Chen MF
Jpn J Clin Oncol; 2008 Feb; 38(2):99-105. PubMed ID: 18270380
[TBL] [Abstract][Full Text] [Related]
5. Predictive role of midtreatment changes in survivin, GSTP1, and topoisomerase 2α expressions for pathologic complete response to neoadjuvant chemotherapy in patients with locally advanced breast cancer.
Eralp Y; Keskin S; Akışık E; Akışık E; İğci A; Müslümanoğlu M; Yılmaz S; Tunacı M; Çamlıca H; Tuzlalı S; Saip P; Dalay N; Özmen V; Topuz E
Am J Clin Oncol; 2013 Jun; 36(3):215-23. PubMed ID: 22441341
[TBL] [Abstract][Full Text] [Related]
6. [Phase II clinical trial of neoadjuvant therapy with carboplatin plus paclitaxel for locally advanced triple-negative breast cancer].
Ma WY; Zhang P; Zhang BL; Wang X; Xu XZ; Zheng S; Wang JY; Cai RG; Yuan P; Ma F; Fan Y; Xu BH
Zhonghua Zhong Liu Za Zhi; 2012 Oct; 34(10):770-4. PubMed ID: 23291072
[TBL] [Abstract][Full Text] [Related]
7. Sequential addition of an anthracycline-based regimen to docetaxel as neoadjuvant chemotherapy in patients with operable breast cancer.
Amat S; Mouret-Reynier MA; Penault-Llorca F; Leheurteur M; Delva R; Coudert B; Leduc B; Dauplat J; Curé H; Chollet P
Clin Breast Cancer; 2006 Aug; 7(3):262-9. PubMed ID: 16942644
[TBL] [Abstract][Full Text] [Related]
8. Prolonged neoadjuvant chemotherapy with GM-CSF in locally advanced breast cancer.
Honkoop AH; Luykx-de Bakker SA; Hoekman K; Meyer S; Meyer OW; van Groeningen CJ; van Diest PJ; Boven E; van der Wall E; Giaccone G; Wagstaff J; Pinedo HM
Oncologist; 1999; 4(2):106-11. PubMed ID: 10337380
[TBL] [Abstract][Full Text] [Related]
9. Effect of neoadjuvant chemotherapy regimen on relapse-free survival among patients with breast cancer achieving a pathologic complete response: an early step in the de-escalation of neoadjuvant chemotherapy.
Weiss A; Bashour SI; Hess K; Thompson AM; Ibrahim NK
Breast Cancer Res; 2018 Apr; 20(1):27. PubMed ID: 29661243
[TBL] [Abstract][Full Text] [Related]
10. [Analysis of the factors affecting pathologic complete response to neoadjuvant chemotherapy in breast cancer patients].
Sun B; Song ST; Jiang ZF; Wang T; Zhang SH; Meng XY; Li XB; Yu CZ; Wu SK
Zhonghua Zhong Liu Za Zhi; 2013 Jan; 35(1):38-42. PubMed ID: 23648298
[TBL] [Abstract][Full Text] [Related]
11. Comparison of Pathologic Response Evaluation Systems after Anthracycline with/without Taxane-Based Neoadjuvant Chemotherapy among Different Subtypes of Breast Cancers.
Lee HJ; Park IA; Song IH; Kim SB; Jung KH; Ahn JH; Ahn SH; Kim HH; Gong G
PLoS One; 2015; 10(9):e0137885. PubMed ID: 26394326
[TBL] [Abstract][Full Text] [Related]
12. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort.
Gianni L; Eiermann W; Semiglazov V; Manikhas A; Lluch A; Tjulandin S; Zambetti M; Vazquez F; Byakhow M; Lichinitser M; Climent MA; Ciruelos E; Ojeda B; Mansutti M; Bozhok A; Baronio R; Feyereislova A; Barton C; Valagussa P; Baselga J
Lancet; 2010 Jan; 375(9712):377-84. PubMed ID: 20113825
[TBL] [Abstract][Full Text] [Related]
13. Phase II study of neoadjuvant treatment with doxorubicin, docetaxel, and capecitabine (ATX) in locally advanced or inflammatory breast cancer.
Manga GP; Shahi PK; Ureña MM; Pereira RQ; Plaza MI; Peron YI; Val RG; Carrión JB; Cañón EP; Alfonso PG
Breast Cancer; 2010 Jul; 17(3):205-11. PubMed ID: 19551465
[TBL] [Abstract][Full Text] [Related]
14. Relationship of clinical and pathologic response to neoadjuvant chemotherapy and outcome of locally advanced breast cancer.
Gajdos C; Tartter PI; Estabrook A; Gistrak MA; Jaffer S; Bleiweiss IJ
J Surg Oncol; 2002 May; 80(1):4-11. PubMed ID: 11967899
[TBL] [Abstract][Full Text] [Related]
15. Phase II study of liposome-encapsulated doxorubicin plus cyclophosphamide, followed by sequential trastuzumab plus docetaxel as primary systemic therapy for breast cancer patients with HER2 overexpression or amplification.
Saracchini S; Foltran L; Tuccia F; Bassini A; Sulfaro S; Micheli E; Del Conte A; Bertola M; Gion M; Lorenzon M; Tumolo S
Breast; 2013 Dec; 22(6):1101-7. PubMed ID: 24074879
[TBL] [Abstract][Full Text] [Related]
16. Primary systemic therapy of breast cancer.
Sachelarie I; Grossbard ML; Chadha M; Feldman S; Ghesani M; Blum RH
Oncologist; 2006 Jun; 11(6):574-89. PubMed ID: 16794237
[TBL] [Abstract][Full Text] [Related]
17. Taxane and anthracycline based neoadjuvant chemotherapy for locally advanced breast cancer: institutional experience.
Gogia A; Raina V; Deo SV; Shukla NK; Mohanti BK; Sharma DN
Asian Pac J Cancer Prev; 2014; 15(5):1989-92. PubMed ID: 24716923
[TBL] [Abstract][Full Text] [Related]
18. Detection of disseminated tumor cells in locally advanced breast cancer patients before primary systemic therapy.
Solá M; Margelí M; Castellá E; Cirauqui B; Mariscal A; Rull M; Julian JF; Luna M; Vallejo V; Fraile M
Breast; 2013 Oct; 22(5):908-13. PubMed ID: 23683695
[TBL] [Abstract][Full Text] [Related]
19. Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study.
Untch M; Rezai M; Loibl S; Fasching PA; Huober J; Tesch H; Bauerfeind I; Hilfrich J; Eidtmann H; Gerber B; Hanusch C; Kühn T; du Bois A; Blohmer JU; Thomssen C; Dan Costa S; Jackisch C; Kaufmann M; Mehta K; von Minckwitz G
J Clin Oncol; 2010 Apr; 28(12):2024-31. PubMed ID: 20308670
[TBL] [Abstract][Full Text] [Related]
20. [Retrospective analysis of trastuzumab treatment in 141 patients with Her-2 positive breast cancer].
Wang Y; Li JJ; DI GH; Lu JS; Wu J; Liu GY; Hu XC; Wang ZH; Yang WT; Shao ZM
Zhonghua Zhong Liu Za Zhi; 2010 Nov; 32(11):864-7. PubMed ID: 21223695
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]